Primate Study Nears Completion.VANCOUVER, British Columbia--(BUSINESS WIRE)--Nov. 3, 1998-- Victor Jones, President, reports that the blood plasma blood plasma n. The yellow or gray-yellow, protein-containing fluid portion of blood in which the blood cells and platelets are normally suspended. and tissue sampling has been completed on its phase II primate study of its proprietary monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing 1F7. The study of the effects of mAb 1F7 on the immune system of macaques infected with a simian form of HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. follows on from an earlier study in macaques which showed beneficial effects of mAb 1F7. In that study mAb 1F7 appeared to increase the breadth and potency of the immune response, increase virus neutralizing antibodies and normalize normalize to convert a set of data by, for example, converting them to logarithms or reciprocals so that their previous non-normal distribution is converted to a normal one. the immune response against the SHIV viral infection. The macaque macaque (məkäk`), name for Old World monkeys of the genus Macaca, related to mangabeys, mandrills, and baboons. All but one of the 19 species are found in Asia from Afghanistan to Japan, the Philippines, and Borneo. monkey is a preferred animal model for the study of HIV disease in humans. Arrangements have been made to analyze all of the plasma samples taken over the six month term of the macaque study using specialized equipment for low threshold detection of SHIV virus (viral load) and other measures of immune response to determine whether mAb 1F7 promotes restoration of an already impaired immune system. The study included a second series of injections of mAb 1F7 which may yield valuable data on repeated use of mAb 1F7 and characterization of mAb 1F7. A study of the effects of mAb 1F7 on the lymph nodes is also underway in collaboration with a university researcher. All animals survived the study and continue to be under close observation as part of related work by researchers at Harvard University. Certain animals may be used in further research in support of the application for the human clinical trial of mAb 1F7 under an Investigational New Drug protocol. The study is under direction of Dr. Sybille Muller of Immpheron, Inc. the company's partner on the mAb 1F7 project. Dr. Muller published results of the earlier study in the prestigious "Proceedings of the National Academy of Science USA" (PNAS PNAS Proceedings of the National Academy of Sciences PNAS Phosphate:Na + Symporter PNAS Pensacola Naval Air Station PNAS Philippine National Airsoft Society Vol. 95 pp. 276-281, January 6, 1998). Results of the just completed study are anticipated in the next few weeks and will similarly be prepared for publication. Planning for further research and the initial human clinical trial is underway. "signed" Victor J. E. Jones President THE VANCOUVER STOCK EXCHANGE Vancouver Stock Exchange (VSE) A securities and options exchange in Vancouver, British Columbia, (Canada), specializing in venture capital companies. Vancouver Stock Exchange See Canadian Venture Exchange (CDNX). HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion